Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Observational Study of Trastuzumab Emtansine Immediately After Trastuzumab Deruxtecan in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Korea

NCT06928818 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT06928818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06928818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Observational Study of Trastuzumab Emtansine Immediately After Trastuzumab Deruxtecan in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Korea
Lead sponsor
Seoul National University Hospital
Phase
Observational
Overall status
Recruiting
Start date
February 26, 2025
Completion date
September 30, 2029
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of breast, trastuzumab deruxtecan, trastuzumab emtansine